Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $209000.0.

  • Utah Medical Products' Depreciation & Amortization (CF) rose 295.57% to $209000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $814000.0, marking a year-over-year increase of 1831.4%. This contributed to the annual value of $730000.0 for FY2024, which is 1717.5% up from last year.
  • Utah Medical Products' Depreciation & Amortization (CF) amounted to $209000.0 in Q3 2025, which was up 295.57% from $205000.0 recorded in Q2 2025.
  • In the past 5 years, Utah Medical Products' Depreciation & Amortization (CF) registered a high of $209000.0 during Q3 2025, and its lowest value of $149000.0 during Q1 2022.
  • For the 5-year period, Utah Medical Products' Depreciation & Amortization (CF) averaged around $169210.5, with its median value being $158000.0 (2021).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first crashed by 858.9% in 2022, then soared by 3096.77% in 2024.
  • Utah Medical Products' Depreciation & Amortization (CF) (Quarter) stood at $153000.0 in 2021, then increased by 3.27% to $158000.0 in 2022, then changed by 0.0% to $158000.0 in 2023, then increased by 26.58% to $200000.0 in 2024, then rose by 4.5% to $209000.0 in 2025.
  • Its last three reported values are $209000.0 in Q3 2025, $205000.0 for Q2 2025, and $200000.0 during Q1 2025.